Biotech startups that raised Series A in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Bioliberty | Edinburgh | Series A | $3.3M | 2026-11-02 |
| Cellbox Solutions | Cologne | Series A | $1.7M | 2026-10-20 |
| Biolevate | Paris | Series A | $34.4M | 2026-09-21 |
| Matisse Pharmaceuticals | Geleen | Series A | $16.0M | 2026-09-17 |
| Amyl Therapeutics | Liège | Series A | $9.6M | 2026-09-01 |
| Adaptyv Biosystems | Lausanne | Series A | $40.0M | 2026-08-25 |
| Kynexis | Naarden | Series A | $112.3M | 2026-08-19 |
| Alchemab Therapeutics | London | Series A | $33.6M | 2026-07-09 |
8 rows of the CSV in 5 of its 18 columns.
- The 488 biotech startups in Europe whose last round is Series A have raised $7.7B in total.
- 61 of them closed their most recent round in the last 12 months, $1.8B combined.
- The largest of those rounds is Coultreon Biopharma's $125.0M Series A, dated April 2026.
- The most recent is Alethio Therapeutics' $90.0M Series A on 5 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 22 of them, more than any other fund.
- Health care is the most common other sector, with 373 companies (76%).
- 21% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (61% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 488| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Bioliberty | Bioliberty develops rehabilitation solutions for degenerative and traumatic conditions as a medtech start-up. | Biotech | Edinburgh, United Kingdom | Series A | $3.3M | 2026-11-02 | $17.4M | Innovate UK, Scottish Enterprise, Old College Capital +2 | 11 to 50 | 2020 |
| Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne, Germany | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
| Biolevate | Biolevate provides an AI platform that helps life sciences teams run regulated operations with auditable workflows. | Artificial intelligence | Paris, France | Series A | $34.4M | 2026-09-21 | $40.7M | Bpifrance, EQT Ventures | 11 to 50 | 2024 |
| Matisse Pharmaceuticals | Matisse Pharmaceuticals develops therapies for sepsis and septic shock by targeting cytotoxic histones. | Biotech | Geleen, The Netherlands | Series A | $16.0M | 2026-09-17 | $22.0M | Brightlands Venture Partners, Chemelot Ventures, Limburg Business Development Fund (LBDF) | 11 to 50 | 2014 |
| Amyl Therapeutics | Amyl Therapeutics is a preclinical biotechnology company developing immunotherapy for neurodegenerative diseases. | Biotech | Liège, Belgium | Series A | $9.6M | 2026-09-01 | $44.0M | Meusinvest (Noshaq), Sambrinvest, Mérieux Equity Partners +1 | 1 to 10 | 2020 |
| Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London, United Kingdom | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| Moleculent | Moleculent is a biotechnology research company. | Biotech | Solna, Sweden | Series A | $20.0M | 2026-04-30 | $46.0M | ARCH Venture Partners, EIR Ventures | 11 to 50 | 2021 |
| mbiomics | mbiomics is a biotechnology company. | Biotech | Munich, Germany | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| Generare | Generare discovers new medicines and valuable molecules from soil bacteria. | Artificial intelligence | Paris, France | Series A | $23.1M | 2026-04-02 | $32.2M | Better Angle, Teampact ventures, Galion.exe +1 | 11 to 50 | 2022 |
| Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Cambridge, United Kingdom | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld, Germany | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| Bon Vivant | Bon Vivant uses precision fermentation to produce real dairy products accessible to everyone. | Biotech | Lyon, France | Series A | $29.4M | 2026-02-24 | $59.6M | Kima Ventures, Picus Capital, Sofinnova Partners +1 | 11 to 50 | 2021 |
| KluraLabs | KluraLabs manufactures products that use nanotechnology to inactivate viruses and bacteria. | Biotech | Haverhill, United Kingdom | Series A | $11.0M | 2026-02-03 | $11.0M | Starship Ventures | 11 to 50 | 2020 |
| Biorce | Biorce develops a clinical AI assistant that speeds up and lowers the cost of clinical trials. | Artificial intelligence | Barcelona, Spain | Series A | $52.0M | 2026-02-02 | $61.5M | Plug and Play, YZR Capital, Outsized Ventures +1 | 11 to 50 | 2024 |
| Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| Octarine Bio | Octarine Bio is a synthetic biology company that produces cannabinoids for the pharmaceutical industry. | Biotech | Copenhagen, Denmark | Series A | $5.9M | 2026-01-22 | $15.5M | MassChallenge, Vaekstfonden, Unconventional Ventures +2 | 11 to 50 | 2018 |
| Luminate Medical | Luminate Medical develops a medical device that prevents hair loss during chemotherapy. | Biotech | Galway, Ireland | Series A | $21.0M | 2026-01-07 | $60.6M | Y Combinator, Pareto Holdings, EIC Accelerator +1 | 11 to 50 | 2018 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury, United Kingdom | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
| Bioxodes | Bioxodes develops high value products derived from natural sources. | Biotech | Marche-en-famenne, Belgium | Series A | $6.4M | 2025-12-10 | $25.6M | European Commission | 11 to 50 | 2013 |
| Pack | Pack is an HR technology platform that supports employee growth through data-driven mentoring and coaching. | Biotech | Barcelona, Spain | Series A | $6.7M | 2025-12-02 | $8.0M | Techstars, Invitalia, Praxi | 11 to 50 | 2022 |
| Qorium | Qorium makes reinvented real leather materials. | Biotech | Maastricht, The Netherlands | Series A | $25.5M | 2025-11-11 | $28.6M | Sofinnova Partners, Brightlands Venture Partners | 11 to 50 | 2021 |
| Adcytherix | Adcytherix is a biopharmaceutical firm developing antibody drug conjugates. | Biotech | Marseille, France | Series A | $122.8M | 2025-10-16 | $155.1M | RA Capital Management, Pureos Bioventures, Pontifax +1 | 11 to 50 | 2023 |
| Genomines | Genomines is a biotechnology company that uses plants for mining. | Biotech | Paris, France | Series A | $45.0M | 2025-09-17 | $61.8M | Bpifrance, Elemental Impact, Lowercarbon Capital | 11 to 50 | 2021 |
| Comphya | Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. | Biotech | Lausanne, Switzerland | Series A | $4.0M | 2025-07-08 | $14.2M | Venture Kick, Verve Ventures, Nest Collective Foundation | 1 to 10 | 2017 |
| Adiposs | Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. | Biotech | Geneva, Switzerland | Series A | $5.0M | 2025-06-30 | $7.4M | MassChallenge, Venture Kick, FONGIT Innovation Fund +2 | 1 to 10 | 2020 |
| Augustine Therapeutics | Augustine Therapeutics discovers and develops medicines for neuromuscular and neurodegenerative diseases. | Biotech | Leuven, Belgium | Series A | $83.9M | 2025-03-24 | $106.8M | PMV, V-Bio Ventures, VIB | 11 to 50 | 2019 |
Table 1. Biotech startups that raised Series A in Europe: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 488.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| 2 | Biorce | Biorce develops a clinical AI assistant that speeds up and lowers the cost of clinical trials. | Artificial intelligence | Barcelona, Spain | Series A | $52.0M | 2026-02-02 | $61.5M | Plug and Play, YZR Capital, Outsized Ventures +1 | 11 to 50 | 2024 |
| 3 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| 4 | Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| 5 | Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London, United Kingdom | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| 6 | Biolevate | Biolevate provides an AI platform that helps life sciences teams run regulated operations with auditable workflows. | Artificial intelligence | Paris, France | Series A | $34.4M | 2026-09-21 | $40.7M | Bpifrance, EQT Ventures | 11 to 50 | 2024 |
| 7 | Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| 8 | EpilepsyGTx | EpilepsyGTx develops gene therapies to improve management of focal refractory epilepsy in late-stage clinical development. | Biotech | Canterbury, United Kingdom | Series A | $33.0M | 2025-12-10 | $43.0M | UCL Technology Fund, HTH | 1 to 10 | 2021 |
| 9 | Bon Vivant | Bon Vivant uses precision fermentation to produce real dairy products accessible to everyone. | Biotech | Lyon, France | Series A | $29.4M | 2026-02-24 | $59.6M | Kima Ventures, Picus Capital, Sofinnova Partners +1 | 11 to 50 | 2021 |
| 10 | Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series A in Europe: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 22 | 5% | 2 | mbiomics, Kupando |
| 2 | Venture Kick | Startup incubator | Schlieren, Switzerland | 10 | 2% | 1 | Adaptyv Biosystems |
| 3 | Bpifrance | Government investment office | Maisons-alfort, France | 8 | 2% | 1 | Biolevate |
| 4 | Sofinnova Partners | Venture capital firm | Paris, France | 7 | 1% | 1 | Bon Vivant |
| 5 | European Innovation Council | Startup accelerator | Brussels, Belgium | 6 | 1% | 1 | Cellbox Solutions |
| 6 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 6 | 1% | 1 | FoRx Therapeutics |
| 7 | KfW | Government investment office | Frankfurt, Germany | 6 | 1% | ||
| 8 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 5 | 1% | 3 | Bioliberty, Apoha, Lucida Medical |
| 9 | Foundation for Innovation and Technology (FIT) | Entrepreneurship program | Lausanne, Switzerland | 5 | 1% | 1 | Adaptyv Biosystems |
| 10 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 5 | 1% | 1 | Kynexis |
| 11 | RA Capital Management | Startup incubator | Boston, United States | 5 | 1% | 1 | Alchemab Therapeutics |
| 12 | Bayern Kapital | Venture capital firm | Landshut, Germany | 5 | 1% | 1 | mbiomics |
| 13 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 1% | 2 | Adaptyv Biosystems, Luminate Medical |
| 14 | EIC Accelerator | Startup accelerator | Brussels, Belgium | 4 | 1% | 1 | Luminate Medical |
| 15 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 4 | 1% | 1 | FoRx Therapeutics |
Table 3. Biotech startups that raised Series A in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 373 | 76% | $6.6B |
| Software | 56 | 11% | $596.5M |
| Artificial intelligence | 29 | 6% | $506.5M |
| Hardware | 20 | 4% | $105.7M |
| Education | 5 | 1% | $20.3M |
| Fintech | 5 | 1% | $28.3M |
| Energy | 3 | 1% | |
| Commerce | 1 | 0% | $11.0M |
| Cybersecurity | 1 | 0% |
Table 4. Biotech startups that raised Series A in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 488 | 100% | $11.3M |
Table 5. Biotech startups that raised Series A in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 125 | 26% |
| France | 76 | 16% |
| Germany | 58 | 12% |
| Switzerland | 56 | 11% |
| The Netherlands | 31 | 6% |
| Belgium | 25 | 5% |
| Denmark | 22 | 5% |
| Italy | 16 | 3% |
| Spain | 15 | 3% |
| Austria | 15 | 3% |
| Sweden | 12 | 2% |
| Ireland | 9 | 2% |
Table 6. Biotech startups that raised Series A in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups that raised Series A in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 3 | 5% | $138.2M |
| October 2026 | 5 | 8% | $49.3M |
| September 2026 | 10 | 16% | $168.4M |
| August 2026 | 2 | 3% | $152.3M |
| July 2026 | 4 | 7% | $68.4M |
| June 2026 | 4 | 7% | $274.0M |
| May 2026 | 2 | 3% | $106.0M |
| April 2026 | 5 | 8% | $200.6M |
| March 2026 | 5 | 8% | $136.4M |
| February 2026 | 5 | 8% | $139.5M |
| January 2026 | 7 | 11% | $132.1M |
| December 2025 | 9 | 15% | $277.2M |
Table 8. Biotech startups that raised Series A in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 52 | 11% | $1.6B |
| 2025 | 52 | 11% | $2.0B |
| 2024 | 58 | 12% | $1.3B |
| 2023 | 45 | 9% | $1.1B |
| 2022 | 37 | 8% | $731.6M |
| 2021 | 45 | 9% | $864.1M |
Table 9. Biotech startups that raised Series A in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 21 | 4% |
| 2020 to 2022 | 83 | 17% |
| 2015 to 2019 | 183 | 38% |
| 2010 to 2014 | 113 | 23% |
| Before 2010 | 84 | 17% |
Table 10. Biotech startups that raised Series A in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 149 | 31% |
| 11 to 50 | 290 | 61% |
| 51 to 100 | 28 | 6% |
| 101 to 250 | 7 | 1% |
| 251 to 500 | 2 | 0% |
| 501 to 1,000 | 2 | 0% |
Table 11. Biotech startups that raised Series A in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Europe. On 16 November 2026 that is 488 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 488 rows: 62 have no round amount, 0 no city and 161 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Europe whose last round is Series A are on the list?
- 488, in the file dated 16 November 2026. 61 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 488 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.